uniQure N.V. Number of Operating Segments
uniQure N.V. (QURE) reported Number of Operating Segments of 1 segment for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-05.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfOperatingSegments · last filed 2026-05-05
- uniQure N.V. number of operating segments for the quarter ending 2026-03-31 was 1.00 segment, a 0.00% change year-over-year.
- uniQure N.V. number of operating segments for the quarter ending 2025-03-31 was 1.00 segment.
- uniQure N.V. number of operating segments for fiscal 2025 was 1.00 segment, a 0.00% change from fiscal 2024.
- uniQure N.V. number of operating segments for fiscal 2024 was 1.00 segment, a 0.00% change from fiscal 2023.
- uniQure N.V. number of operating segments for fiscal 2023 was 1.00 segment, a 0.00% change from fiscal 2022.
- uniQure N.V. number of operating segments for fiscal 2022 was 1.00 segment, a 0.00% change from fiscal 2021.
| Period end | Number of Operating Segments 3 month | Number of Operating Segments 6 month | Number of Operating Segments 9 month | Number of Operating Segments 12 month |
|---|---|---|---|---|
| 2026-03-31 | 1.00 segment 10-Q · filed 2026-05-05 | |||
| 2025-12-31 | 1.00 segment 10-K · filed 2026-03-02 | |||
| 2025-09-30 | 1.00 segment 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | 1.00 segment 10-Q · filed 2025-07-29 | |||
| 2025-03-31 | 1.00 segment 10-Q · filed 2025-05-09 | |||
| 2024-12-31 | 1.00 segment 10-K · filed 2025-02-27 | |||
| 2023-12-31 | 1.00 segment 10-K · filed 2024-02-28 | |||
| 2022-12-31 | 1.00 segment 10-K · filed 2023-02-27 | |||
| 2021-12-31 | 1.00 segment 10-K · filed 2022-02-25 | |||
| 2020-12-31 | 1.00 segment 10-K · filed 2021-03-01 | |||
| 2019-12-31 | 1.00 segment 10-K · filed 2020-03-02 | |||
| 2018-12-31 | 1.00 segment 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |